Cargando…

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis

Interferon beta (IFNβ) is the most common immunomodulatory treatment for relapsing-remitting multiple sclerosis (RRMS). However, some patients fail to respond to treatment. In this study, we identified putative clinical response markers in the serum and plasma of people with multiple sclerosis (MS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gandhi, Kaushal S., McKay, Fiona C., Diefenbach, Eve, Crossett, Ben, Schibeci, Stephen D., Heard, Robert N., Stewart, Graeme J., Booth, David R., Arthur, Jonathan W.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864746/ https://www.ncbi.nlm.nih.gov/pubmed/20463963 http://dx.doi.org/10.1371/journal.pone.0010484

Ejemplares similares

IL7Rα Expression and Upregulation by IFNβ in Dendritic Cell Subsets Is Haplotype-Dependent
por: McKay, Fiona C., et al.
Publicado: (2013)

Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility
por: Afrasiabi, Ali, et al.
Publicado: (2019)

Expression of CYP24A1 and other multiple sclerosis risk genes in peripheral blood indicates response to vitamin D in homeostatic and inflammatory conditions
por: Law, Samantha P. L., et al.
Publicado: (2021)

First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia
por: Zhou, Li, et al.
Publicado: (2010)

A Transcription Factor Map as Revealed by a Genome-Wide Gene Expression Analysis of Whole-Blood mRNA Transcriptome in Multiple Sclerosis
por: Riveros, Carlos, et al.
Publicado: (2010)

The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function
por: Field, Judith, et al.
Publicado: (2015)

Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission
por: Arthur, Ariel T, et al.
Publicado: (2008)

An investigation of polymorphisms in the 17q11.2-12 CC chemokine gene cluster for association with multiple sclerosis in Australians
por: Bugeja, Matthew J, et al.
Publicado: (2006)

Age-dependent VDR peak DNA methylation as a mechanism for latitude-dependent multiple sclerosis risk
por: Ong, Lawrence T. C., et al.
Publicado: (2021)

Differences in common heritable blood immune cell populations may underlie MS susceptibility and progression
por: Booth, David R, et al.
Publicado: (2016)

Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation
por: Katzeff, Jared S., et al.
Publicado: (2020)

Macrophage Coordination of the Interferon Lambda Immune Response
por: Read, Scott A., et al.
Publicado: (2019)

Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis
por: Fewings, N., et al.
Publicado: (2017)

Oral contraceptives combined with interferon β in multiple sclerosis
por: Pozzilli, Carlo, et al.
Publicado: (2015)

The Interaction of Human and Epstein–Barr Virus miRNAs with Multiple Sclerosis Risk Loci
por: Afrasiabi, Ali, et al.
Publicado: (2021)

A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis
por: Field, Judith, et al.
Publicado: (2010)

The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype
por: Keane, Jeremy Thomas, et al.
Publicado: (2021)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Gender and the Sex Hormone Estradiol Affect Multiple Sclerosis Risk Gene Expression in Epstein-Barr Virus-Infected B Cells
por: Keane, Jeremy T., et al.
Publicado: (2021)

Early stage and long term treatment of multiple sclerosis with interferon-β
por: Applebee, Angela, et al.
Publicado: (2009)

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
por: Kolb-Mäurer, Annette, et al.
Publicado: (2015)

Differential serum interferon-β levels in autoimmune thyroid diseases
por: Cheng, Chao-Wen, et al.
Publicado: (2021)

The potential of serum neurofilament as biomarker for multiple sclerosis
por: Bittner, Stefan, et al.
Publicado: (2021)

Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2022)

Endogenous Interferon-β-Inducible Gene Expression and Interferon-β-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2015)

Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
por: Hegen, Harald, et al.
Publicado: (2016)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
por: Kakkar, Vishal, et al.
Publicado: (2022)

Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008)

Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis
por: Zhornitsky, Simon, et al.
Publicado: (2015)

Bone marrow sarcoidosis associated with long‐term interferon‐β treatment for multiple sclerosis
por: Teh, Angela, et al.
Publicado: (2016)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
por: Simpson-Yap, Steve, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_je1l4d5n3ma5tec0qbdf4kroc8